|
Delayed
London S.E.
11:35:23 2026-08-28 am EDT
|
5-day change | 1st Jan Change | ||
| 1,853.50 GBX | +0.08% |
|
-3.39% | +1.59% |
| Aug. 27 | FTSE down as inflation fear offsets Nvidia lift | AN |
| Aug. 27 | European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading | MT |
| Market Cap | 74.27B 101B 86.78B 81.36B 140B 9,625B 140B 965B 377B 4,858B 378B 370B 16,110B | P/E 2026 * |
14x | P/E 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 94.11B 128B 110B 103B 177B 12,195B 178B 1,223B 477B 6,156B 479B 469B 20,413B | EV / Sales 2026 * |
2.77x | EV / Sales 2027 * | 2.57x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
Last Transcript : GSK plc
| Aug. 25 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 20 | Cancer vaccines finally garner the spotlight |  |
| Aug. 19 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 17 | GSK Kept at Hold as Berenberg Notes Cost Savings Plan | MT |
| Aug. 17 | GSK plc : Berenberg gives a Neutral rating | ZD |
| 1 day | +0.08% | ||
| 1 week | -3.39% | ||
| Current month | -4.04% | ||
| 1 month | -4.46% | ||
| 3 months | -1.49% | ||
| 6 months | -14.98% | ||
| Current year | +1.59% |
| 1 week | 1,839 |  | 1,919.5 |
| 1 month | 1,803 | | 1,972 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,440.29 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/29/26 | Sell | Executive/Senior Manager | -38,000 | 0.0009% | ||
| 7/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 7/14/26 | Buy | Chief Technology Officer | 660 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.08% | -3.39% | +27.61% | +32.62% | 101B | |
| -1.88% | -7.32% | +57.19% | +108.52% | 1,047B | |
| -0.25% | -2.47% | +49.56% | +64.71% | 646B | |
| -0.24% | -3.74% | +20.15% | +73.26% | 451B | |
| -1.58% | -4.59% | +35.82% | +35.77% | 355B | |
| -0.53% | -2.95% | +21.15% | +37.74% | 291B | |
| -1.19% | -2.21% | +1.53% | +11.51% | 252B | |
| -0.35% | -3.27% | +49.63% | +67.48% | 234B | |
| -1.47% | -2.82% | -20.35% | -54.35% | 203B | |
| -1.38% | -2.01% | +27.58% | +88.01% | 181B | |
| Average | -1.00% | -2.75% | +26.99% | +46.53% | 376B | |
| Weighted average by Cap. | -1.18% | -3.46% | +36.03% | +63.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 46.01B 39.65B 37.18B 63.93B 4,398B 64.13B 441B 172B 2,220B 173B 169B 7,361B | 35.52B 48.16B 41.5B 38.91B 66.91B 4,602B 67.12B 462B 180B 2,323B 181B 177B 7,704B |
| Net income | 5.44B 7.37B 6.35B 5.95B 10.24B 704B 10.27B 70.65B 27.56B 356B 27.67B 27.07B 1,179B | 6.48B 8.79B 7.58B 7.1B 12.22B 840B 12.25B 84.28B 32.88B 424B 33.01B 32.29B 1,406B |
| Net Debt | 19.84B 26.9B 23.18B 21.73B 37.37B 2,571B 37.49B 258B 101B 1,298B 101B 98.79B 4,303B | 17.06B 23.13B 19.93B 18.69B 32.14B 2,211B 32.24B 222B 86.51B 1,116B 86.85B 84.96B 3,700B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-28 | GBX 1,853.50 | +0.08% | 7,790,314 |
| 26-08-27 | GBX 1,852.00 | -2.50% | 3,594,876 |
| 26-08-26 | GBX 1,899.50 | -0.31% | 3,466,438 |
| 26-08-25 | GBX 1,905.50 | +0.79% | 4,599,767 |
| 26-08-24 | GBX 1,890.50 | -1.46% | 5,275,639 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
